File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation

TitleHepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation
Authors
KeywordsDe-novo hepatitis B virus infection
Prophylactic therapy
Transplantation
Issue Date2006
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-transplantation.com
Citation
Current Opinion In Organ Transplantation, 2006, v. 11 n. 6, p. 594-598 How to Cite?
AbstractPURPOSE OF REVIEW: The risk of de-novo hepatitis B virus infection from the use of hepatitis B core antibody-positive liver grafts has been reported to vary from 16 to 50%, leading to many transplant centres excluding the use of hepatitis B core antibody-positive livers, severely limiting the number of available livers. This paper reviews the use of a prophylactic regimen to prevent the occurrence of de-novo hepatitis B after liver transplantation. RECENT FINDINGS: Combination prophylaxis with human immune globulin and lamivudine was found to reduce the occurrence of hepatitis B in recipients of hepatitis B core antibody-positive liver grafts. Whether lamivudine monoprophylaxis alone is adequate in preventing de-novo hepatitis B from hepatitis B core antibody-positive liver allografts still requires investigation. Additional studies have found that protective titres of hepatitis B surface antibody can protect against de-novo hepatitis B. The results of vaccinating cirrhosis patients awaiting liver transplantation have so far been disappointing. Third-generation hepatitis B vaccine containing pre-S1/S2 recombinant antigens may improve success rates. SUMMARY: Future studies should focus on establishing the best prophylactic regimen for the prevention of hepatitis B so that the donor pool can be expanded to include hepatitis B core antibody-positive donors. © 2006 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/84014
ISSN
2015 Impact Factor: 2.68
2015 SCImago Journal Rankings: 1.088
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorCheung, WWen_HK
dc.contributor.authorChan, SCen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorLau, GKen_HK
dc.date.accessioned2010-09-06T08:47:54Z-
dc.date.available2010-09-06T08:47:54Z-
dc.date.issued2006en_HK
dc.identifier.citationCurrent Opinion In Organ Transplantation, 2006, v. 11 n. 6, p. 594-598en_HK
dc.identifier.issn1087-2418en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84014-
dc.description.abstractPURPOSE OF REVIEW: The risk of de-novo hepatitis B virus infection from the use of hepatitis B core antibody-positive liver grafts has been reported to vary from 16 to 50%, leading to many transplant centres excluding the use of hepatitis B core antibody-positive livers, severely limiting the number of available livers. This paper reviews the use of a prophylactic regimen to prevent the occurrence of de-novo hepatitis B after liver transplantation. RECENT FINDINGS: Combination prophylaxis with human immune globulin and lamivudine was found to reduce the occurrence of hepatitis B in recipients of hepatitis B core antibody-positive liver grafts. Whether lamivudine monoprophylaxis alone is adequate in preventing de-novo hepatitis B from hepatitis B core antibody-positive liver allografts still requires investigation. Additional studies have found that protective titres of hepatitis B surface antibody can protect against de-novo hepatitis B. The results of vaccinating cirrhosis patients awaiting liver transplantation have so far been disappointing. Third-generation hepatitis B vaccine containing pre-S1/S2 recombinant antigens may improve success rates. SUMMARY: Future studies should focus on establishing the best prophylactic regimen for the prevention of hepatitis B so that the donor pool can be expanded to include hepatitis B core antibody-positive donors. © 2006 Lippincott Williams & Wilkins, Inc.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.co-transplantation.comen_HK
dc.relation.ispartofCurrent Opinion in Organ Transplantationen_HK
dc.rightsThis is a non-final version of an article published in final form in Current Opinion in Organ Transplantation, 2006, v. 11 n. 6, p. 594-598en_HK
dc.subjectDe-novo hepatitis B virus infectionen_HK
dc.subjectProphylactic therapyen_HK
dc.subjectTransplantationen_HK
dc.titleHepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1087-2418&volume=11&issue=6&spage=594&epage=598&date=2006&atitle=Hepatitis+B+vaccination+and+preemptive+treatment+of+hepatitis+B+virus+in+liver+transplantationen_HK
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.authorityChan, SC=rp01568en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/MOT.0b013e32801040bfen_HK
dc.identifier.scopuseid_2-s2.0-33751240093en_HK
dc.identifier.hkuros136094en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33751240093&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume11en_HK
dc.identifier.issue6en_HK
dc.identifier.spage594en_HK
dc.identifier.epage598en_HK
dc.identifier.isiWOS:000242704600004-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridCheung, WW=8615134400en_HK
dc.identifier.scopusauthoridChan, SC=7404255575en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridLau, GK=7102301257en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats